Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: A study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder

Early Intervention in Psychiatry

Volumn 7, Issue 4, 2013, Pages 374-380

  Dell'Osso, Bernardo ^a   Camuri, Giulia ^a   Benatti, Beatrice ^a   Buoli, Massimiliano ^a   Altamura, A Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Duration of untreated illness; Early intervention; Generalized anxiety disorder; Obsessive compulsive disorder; Panic disorder

Indexed keywords

CLOMIPRAMINE; HYDROXYZINE; IMIPRAMINE; NEUROLEPTIC AGENT; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DSM-IV-TR; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PANIC; PRIORITY JOURNAL; TREATMENT DURATION;

DURATION OF UNTREATED ILLNESS; EARLY INTERVENTION; GENERALIZED ANXIETY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER;

ADULT; AGE FACTORS; AGE OF ONSET; ANXIETY DISORDERS; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; TIME FACTORS;

EID: 84886750640     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12016     Document Type: Article

References (44)

1. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; (12): CD008120.
2. Baldwin DS, Allgulander C, Altamura AC etal. Manifesto for European anxiety disorders research network. Eur Neuropsychopharmacol 2010; 20: 426-432.
3. Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 327-337.
4. Kessler RC, McGonagle KA, Zhao S etal. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbid Survey. Arch Gen Psychiatry 1994; 51: 8-19.
5. Lieb R, Becker E, Altamura AC. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15: 445-452.
6. Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev 2007; 27: 572-581.
7. Altamura AC, Camuri G, Dell'osso B. Understanding the role of the duration of untreated illness in psychiatric disorders: a narrative review. Riv Psichiatr 2010; 45: 197-208.
8. Wagner R, Silove D, Marnane C, Rouen D. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord 2006; 20: 363-371.
9. Dell'osso B, Altamura AC. Duration of untreated psychosis and duration of untreated illness: new vistas. CNS Spectr 2010; 15: 238-246.
10. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF, Langarica M. Duration of untreated psychotic illness: the role of premorbid social support networks. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 345-349.
11. Compton MT, Carter T, Bergner E etal. Defining, operationalizing and measuring the duration of untreated psychosis: advances, limitations and future directions. Early Interv Psychiatry 2007; 1: 236-250.
12. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-1804.
13. Dell'osso B, Glick ID, Baldwin D, Altamura AC. Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework. Psychopathology 2013; 46: 14-21.
14. Dell'osso B, Buoli B, Hollander E, Altamura AC. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatry 2010; 11: 59-65.
15. Altamura AC, Santini A, Salvadori D, Mundo E. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr Dis Treat 2005; 1: 345-347.
16. Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr 2008; 13: 415-422.
17. Altamura AC, Buoli M, Albano A, Dell'osso B. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int Clin Psychopharmacol 2010; 25: 172-179.
18. Christensen H, Pallister E, Smale S, Hickie IB, Calear AL. Community-based prevention programs for anxiety and depression in youth: a systematic review. J Prim Prev 2010; 31: 139-170.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Publishing, Inc., 2000.
20. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP) New York: Biometrics Research, New York State Psychiatric Institute, November, 2002.
21. First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press, Inc., 1997.
22. Altamura AC, Dell'osso B, Berlin HA, Buoli M, Bassetti R, Mundo E. Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2010; 260: 385-391.
23. Dell'osso B, Palazzo MC, Arici C etal. Sviluppo di un questionario per la valutazione dell'esordio psicopatologico e della latenza ai trattamenti, Abstract presented in Rome, SOPSI, 2011.
24. Dell'osso B, Arici C, Dobrea C. Validation of a brief questionnaire for the assessment of the onset and latency to treatments of psychiatric disorders. Poster Abstract presented at the 10th World Congress of Biological Psychiatry. Published in the abstract CD-ROM as P-28-014, 2011.
25. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171-199.
26. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. Clin Psychiatry 2009; 70: 25-31.
27. Koran LM, Hanna GL, Hollander E, Nestadtm G, Simpsonm HB, American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164: 5-53.
28. Simpson HB. Pharmacological treatment of obsessive-compulsive disorder. Curr Top Behav Neurosci 2010; 2: 527-543.
29. Keck PE Jr, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 2006; 67: 8-15.
30. Kinrys G, Wygant LE. Anxiety disorders in women: does gender matter to treatment? Rev Bras Psiquiatr 2005; 27: S43-50.
31. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001; 158: 1568-1578.
32. Pallanti S, Hollander E. Obsessive-compulsive disorder spectrum as a scientific 'metaphor'. CNS Spectr 2008; 13: 6-15.
33. Katerndahl DA, Realini JP. Use of health care services by persons with panic symptoms. Psychiatr Serv 1997; 48: 1027-1032.
34. Kaplan ME, Dupont RL. Benzodiazepines and anxiety disorders: a review for the practicing physician. Curr Med Res Opin 2005; 21: 941-950.
35. Swinson RP, Soulios C, Cox BJ, Kuch K. Brief treatment of emergency room patients with panic attacks. Am J Psychiatry 1992; 149: 944-946.
36. Simonds LM, Thorpe SJ. Attitudes toward obsessive-compulsive disorders: an experimental investigation. Soc Psychiatry Psychiatr Epidemiol 2003; 38: 331-336.
37. Van der Heiden C, Methorst G, Muris P, van der Molen HT. Generalized anxiety disorder: clinical presentation, diagnostic features, and guidelines for clinical practice. J Clin Psychol 2011; 67: 58-73.
38. Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. J Clin Psychiatry 2002; 63: 35-42.
39. Rapee RM. Generalized anxiety disorder: a review of clinical features and theoretical concepts. Clin Psychol Rev 1991; 11: 419-440.
40. Wittchen HU, Essau CA, Krieg JC. Anxiety disorders: similarities and differences of comorbidity in treated and untreated groups. Br J Psychiatry 1991; 159: 23-33.
41. Noyes R, Woodman C, Garvey MJ etal. Generalized anxiety disorder versus panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 1992; 180: 369-379.
42. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16: 162-171.
43. Dugas MJ, Anderson KG, Deschenes SS, Donegan E. Generalized anxiety disorder publications: where do we stand a decade later? J Anxiety Disord 2010; 24: 780-784.
44. Singh SP. Outcome measures in early psychosis; relevance of duration of untreated psychosis. Br J Psychiatry Suppl 2007; 50: s58-63.